Phaseline

Companies › Royal Biologics

Royal Biologics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Amnio-Maxx® Dual Layer Amnion Patch
Cellular, acellular, matrix-like product (CAMP) derived from human amnion
–Phase 4Diabetic Foot Ulcer (DFU)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07209475Amnio-Maxx® Dual Layer Amnion PatchPhase 4Diabetic Foot Ulcer (DFU)Metabolic and endocrineAug 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

PolarityTE HealthTech Wound Care Ascendis Pharma Bone Diseases BioXTek Blue Blood Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.